Stockreport

Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial [Yahoo! Finance]

Evaxion A/S - American Depositary Share  (EVAX) 
PDF The results reinforce that Evaxion's pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targets Data will be presented [Read more]